Marksans Pharma Limited — Cetirizine Exporter Profile
Indian Pharmaceutical Exporter · #6 for Cetirizine · $7.7M export value · DGFT Verified
Marksans Pharma Limited is the #6 Indian exporter of Cetirizine with $7.7M in export value and 338 verified shipments. Marksans Pharma Limited holds a 4.3% market share in Cetirizine exports across 6 countries. The company exports 22 pharmaceutical products worth $125.0M across 11 therapeutic categories.
Marksans Pharma Limited — Cetirizine Export Profile: Buyers & Destinations
Where Does Marksans Pharma Limited Export Cetirizine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED KINGDOM | $4.6M | 167 | 60.6% |
| UNITED STATES | $2.6M | 136 | 34.2% |
| AUSTRALIA | $328.2K | 37 | 4.4% |
| CAMBODIA | $49.2K | 11 | 0.7% |
| IRAQ | $7.0K | 1 | 0.1% |
| AFGHANISTAN | $4.1K | 1 | 0.1% |
Marksans Pharma Limited exports Cetirizine to 6 countries. The largest destination is UNITED KINGDOM accounting for 60.6% of Marksans Pharma Limited's Cetirizine shipments, followed by UNITED STATES (34.2%) and AUSTRALIA (4.4%). These destinations reflect Marksans Pharma Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Cetirizine from Marksans Pharma Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| RELONCHEM LTD CHESHIRE HOUSE, | UNITED KINGDOM | $2.3M | 83 |
| TIME-CAP LABS, | UNITED STATES | $1.6M | 72 |
| RELONCHEM LTD | UNITED KINGDOM | $1.5M | 54 |
| RELONCHEM LIMITED | UNITED KINGDOM | $596.9K | 28 |
| TIME-CAP LABS INC | UNITED STATES | $411.3K | 27 |
| TIME-CAP LABS | UNITED STATES | $243.6K | 20 |
| NOVA PHARMACEUTICALS AUSTRALASIA | AUSTRALIA | $230.9K | 22 |
| TIME CAP LABS | UNITED STATES | $161.8K | 6 |
| TIME-CAP LABS, INC | UNITED STATES | $89.6K | 7 |
| NOVA PHARMACEUTICALS AUSTRALASIA PT | AUSTRALIA | $84.3K | 9 |
Marksans Pharma Limited supplies Cetirizine to 19 buyers globally. The largest buyer is RELONCHEM LTD CHESHIRE HOUSE, (UNITED KINGDOM), followed by TIME-CAP LABS, (UNITED STATES) and RELONCHEM LTD (UNITED KINGDOM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Cetirizine Export Value and How Much Does Marksans Pharma Limited Contribute?
India exported $82.1M worth of Cetirizine through 8,785 shipments from 649 suppliers to 149 countries, serving 1,814 buyers globally. Marksans Pharma Limited contributes $7.7M to this total, accounting for 4.3% of India's Cetirizine exports. Marksans Pharma Limited ships Cetirizine to 6 countries through 19 buyers.
What Is the Average Shipment Value for Marksans Pharma Limited's Cetirizine Exports?
Marksans Pharma Limited's average Cetirizine shipment value is $22.8K per consignment, based on 338 shipments totaling $7.7M. The largest destination is UNITED KINGDOM (60.6% of Marksans Pharma Limited's Cetirizine exports).
How Does Marksans Pharma Limited Compare to Other Indian Cetirizine Exporters?
Marksans Pharma Limited ranks #6 among 649 Indian Cetirizine exporters with a 4.3% market share. The top 3 exporters are DR.REDDY'S LABORATORIES LTD ($9.8M), MICRO LABS LIMITED ($7.8M), MARKSANS PHARMA LIMITED ($7.7M). Marksans Pharma Limited processed 338 shipments to 6 destination countries.
What Cetirizine Formulations Does Marksans Pharma Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CETIRIZINE HYDROCHLORIDE 10 MG TABLETS B | $885.5K | 31 |
| PHARMACEUTICAL PRODUCTS-CETIRIZINE HYDRO | $639.8K | 25 |
| CETIRIZINE HYDROCHLORIDE TABLETS USP10MG | $558.4K | 23 |
| CETIRIZINE HYDROCHLORIDE TABLETS USP 10M | $90.9K | 8 |
| PHARMACEUTICAL PRODUCTS - CETIRIZINE HYDROCHLORIDE 10 MG TABLETS Batch No: 150115 | $89.5K | 2 |
| PHARMACEUTICAL PRODUCTS - CETIRIZINE HYDROCHLORIDE 10 MG TABLETS BATCH NO: 140532,140534 | $76.7K | 3 |
| PHARMACEUTICAL PRODUCTS -CETIRIZINE HYDROCHLORIDE 10 MG TABLETS BATCH NO: 140442 | $75.5K | 3 |
| PHARMACEUTICAL PRODUCTS - CETIRIZINE HYDROCHLORIDE TABLETS USP10MG BATCH NO: 140769 | $72.3K | 3 |
| PHARMACEUTICAL PRODUCTS - CETIRIZINE HYDROCHLORIDE 10 MG TABLETS Batch No: 150297 | $71.2K | 2 |
| PHARMACEUTICAL PRODUCTS - CETIRIZINE HYDROCHLORIDE 10 MG TABLETS BATCH NO: 140576 | $71.0K | 3 |
Marksans Pharma Limited exports 196 distinct Cetirizine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CETIRIZINE HYDROCHLORIDE 10 MG TABLETS B with 31 shipments worth $885.5K.
Regulatory Requirements: Exporting Cetirizine to Key Markets
What Marksans Pharma Limited must comply with to export Cetirizine to its top destination countries
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Marksans Pharma Limited Compare to Nearest Cetirizine Exporters?
Exporters ranked immediately above and below #6 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | DR.REDDY'S LABORATORIES LTD | $9.8M | 196 | 8 | $50.0K |
| 5 | MICRO LABS LIMITED | $7.8M | 213 | 21 | $36.6K |
| 6 | MARKSANS PHARMA LIMITED ★ | $7.7M | 338 | 6 | $22.8K |
| 7 | J B CHEMICALS AND PHARMACEUTICALS LIMITED | $7.5M | 172 | 3 | $43.7K |
| 8 | HETERO LABS LIMITED | $7.5M | 395 | 31 | $18.9K |
Marksans Pharma Limited ranks #6 among 649 Indian Cetirizine exporters. Average shipment value of $22.8K compared to the market average of $126.5K. The closest competitors by value are DR.REDDY'S LABORATORIES LTD and MICRO LABS LIMITED.
Which Indian Ports Ship Cetirizine Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 986 | 11.2% |
| JNPT/ NHAVA SHEVA SEA | 731 | 8.3% |
| JNPT | 616 | 7.0% |
| SAHAR AIR | 542 | 6.2% |
| SAHAR AIR CARGO ACC (INBOM4) | 491 | 5.6% |
| DELHI AIR CARGO ACC (INDEL4) | 408 | 4.6% |
| DELHI AIR | 381 | 4.3% |
| HYDERABAD ICD | 374 | 4.3% |
What Other Antihistamines & Allergy Products Does Marksans Pharma Limited Export?
Marksans Pharma Limited also exports these antihistamines & allergy products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Marksans Pharma Limited's Cetirizine Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Marksans Pharma. The ongoing Israel-Iran tensions have led to increased security risks in the Red Sea, a crucial maritime route for trade between Asia and Europe. Major shipping lines have introduced an 'Emergency Risk Surcharge' ranging from $250 to $500 per TEU for cargo transiting the Bab-el-Mandeb Strait, effective February 2025. This surcharge elevates shipping costs, potentially impacting the competitiveness of Indian pharmaceutical exports to European and US East Coast markets. (sgeexport.com)
Conversely, the India–European Union Free Trade Agreement (FTA), concluded in January 2026, offers a silver lining. The FTA eliminates tariffs on Indian pharmaceuticals, APIs, vaccines, and medical devices, providing immediate cost relief and enhancing market access for Indian exporters. This development positions Marksans Pharma favorably to increase its footprint in the European market, leveraging its existing regulatory approvals and manufacturing capabilities. (en.wikipedia.org)
Marksans Pharma Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for pharmaceutical exporters. Marksans Pharma has demonstrated a strong commitment to regulatory compliance. In November 2025, the company's Goa facility underwent a current Good Manufacturing Practice (cGMP) inspection by the US FDA, concluding with zero Form 483 observations. This outcome reflects Marksans' dedication to adhering to international quality standards and regulatory requirements. (capitalmarket.com)
Furthermore, the company's subsidiaries have achieved significant regulatory milestones. Time-Cap Laboratories Inc., Marksans' US subsidiary, received an Establishment Inspection Report (EIR) from the US FDA for its New York-based facility in June 2025, following an inspection that resulted in only one observation with no data integrity issues. Such achievements bolster Marksans' reputation as a reliable and compliant pharmaceutical manufacturer. (business-standard.com)
About Marksans Pharma Limited
Marksans Pharma Limited exports 22 products worth $125.0M. Beyond Cetirizine, top products include Ibuprofen, Amino, Gabapentin, Acetaminophen, Loratadine. View the complete Marksans Pharma Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Cetirizine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Cetirizine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Marksans Pharma Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 353 individual customs records matching Marksans Pharma Limited exporting Cetirizine, covering 196 formulations to 6 countries via 19 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 149+ countries, 1,814+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Cetirizine Export Data from Marksans Pharma Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Marksans Pharma Limited's Cetirizine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Marksans Pharma Limited
Full Company Profile →
22 products · $125.0M total trade · 11 categories
Cetirizine Stats
Company Overview
Top Products by Marksans Pharma Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Marksans Pharma Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Cetirizine. For current shipment-level data, contact TransData Nexus.